Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints
Eyenovia said Friday it plans to cut half of its workforce after results from a Phase 3 study missed their primary endpoint. The pharmaceutical company had 57 full-time employees as of March 15. There were no part-time employees. Eyenovia also engages with various consultants and contractors.
(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat ...
Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...
The latest health brief highlights a severe dengue outbreak in Bangladesh, California's first Clade I Mpox case, and Oregon's ...
On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...
William Blair downgraded Eyenovia (EYEN) to Market Perform from Outperform after the review of the CHAPERONE trial data by an independent Data ...
Global health advocates are pressing for cheaper mpox tests to aid poorer countries, while the first clade I mpox case is ...
Revenue missed analyst estimates by 99%. Earnings per share (EPS) also missed analyst estimates by 3.1%. Looking ahead, ...
Announced collaboration agreements with Formosa Pharmaceuticals, Senju Pharmaceutical Co., Ltd. and SGN Nanopharma to develop novel therapeutics for use with Eyenovia’s Optejet® dispenser as ...
Brookline analyst Kemp Dolliver downgraded Eyenovia (EYEN) to Hold from Buy without a price target following the CHAPERONE study failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback